glp 1 agonists and anesthesia ASA Advises No Longer Holding GLP-1 Agents Prior to Surgery for Most Patients GLP-1 agonists: a new hope
Description
Obesity is one of the most common diseases worldwide
Similar concerns apply to GLP-1 RAs, where long-term adherence is essential to maintain both metabolic and hemodynamic benefits
Specifically, vildagliptin forms a transient imidate intermediate with DPP4, stabilized by interactions with Tyr547 and Tyr631 in the S1 subsite
Moreover, several second-generation medicines shown substantial cardiovascular advantages in extensive outcome studies, therefore enhancing their therapeutic efficacy beyond basic glucose regulation (Nauck and Meier 2019)
Weivoda et al
